Terms: = Ovarian cancer AND CCND1, BCL1, 595, ENSG00000110092, PRAD1, U21B31, D11S287E AND Treatment
32 results:
1. A Study on the Retrospective Reinterpretation of BRCA1 and BRCA2 Variants.
Kim JJ; Kim DJ; Nam EJ; Song KE; Ham JY; Kim YK; Lee NY
Clin Lab; 2024 Apr; 70(4):. PubMed ID: 38623660
[TBL] [Abstract] [Full Text] [Related]
2. Mental health and diet quality after primary treatment for ovarian cancer.
Johnston EA; Veenhuizen SGA; Ibiebele TI; Webb PM; van der Pols JC;
Nutr Diet; 2024 Apr; 81(2):215-227. PubMed ID: 38192229
[TBL] [Abstract] [Full Text] [Related]
3. The cost-effectiveness analysis of maintenance olaparib plus Bevacizumab in patients with advanced ovarian cancer: based on the final survival results from PAOLA-1 trial.
Zhu Y; Liu K; Cao H; Zhu H
J Ovarian Res; 2023 Aug; 16(1):168. PubMed ID: 37605274
[TBL] [Abstract] [Full Text] [Related]
4. Anticancer Effect of Active Component of Astragalus Membranaceus Combined with Olaparib on ovarian cancer Predicted by Network-Based Pharmacology.
Liu Y; Guo Z; Lang F; Li J; Jiang J
Appl Biochem Biotechnol; 2023 Nov; 195(11):6994-7020. PubMed ID: 36976504
[TBL] [Abstract] [Full Text] [Related]
5. Enhanced anti-cancer effects of oestrogen and progesterone co-therapy against colorectal cancer in males.
Mahbub AA; Aslam A; Elzubier ME; El-Boshy M; Abdelghany AH; Ahmad J; Idris S; Almaimani R; Alsaegh A; El-Readi MZ; Baghdadi MA; Refaat B
Front Endocrinol (Lausanne); 2022; 13():941834. PubMed ID: 36263327
[TBL] [Abstract] [Full Text] [Related]
6. DDTC Suppresses ovarian cancer Development via the PI3K/AKT/mTOR Signaling Pathway.
Li M; Zhang W; Wang Y; Huang K; Sun T; Qiu Z; Yang L; Wu M; Zhang X; Zhang W
Dis Markers; 2022; 2022():1941077. PubMed ID: 35978887
[TBL] [Abstract] [Full Text] [Related]
7. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
Han L; Guo X; Du R; Guo K; Qi P; Bian H
J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
[TBL] [Abstract] [Full Text] [Related]
8. NAP1L1 promotes tumor proliferation through HDGF/C-JUN signaling in ovarian cancer.
Xiaohua Zhu ; Xie Y; Huang W; Chen Z; Guo S
BMC Cancer; 2022 Mar; 22(1):339. PubMed ID: 35351053
[TBL] [Abstract] [Full Text] [Related]
9. Larotrectinib in a Patient With Advanced Pleomorphic Liposarcoma of the Uterus.
Valenciaga A; Iwenofu OH; Tinoco G
J Natl Compr Canc Netw; 2021 Jul; 19(7):775-779. PubMed ID: 34340207
[TBL] [Abstract] [Full Text] [Related]
10. PSMC2/ccnd1 axis promotes development of ovarian cancer through regulating cell growth, apoptosis and migration.
Zhu D; Huang J; Liu N; Li W; Yan L
Cell Death Dis; 2021 Jul; 12(8):730. PubMed ID: 34294689
[TBL] [Abstract] [Full Text] [Related]
11. Depression and anxiety in cancer patients before and during the SARS-CoV-2 pandemic: association with treatment delays.
Yildirim OA; Poyraz K; Erdur E
Qual Life Res; 2021 Jul; 30(7):1903-1912. PubMed ID: 33635508
[TBL] [Abstract] [Full Text] [Related]
12. MicroRNA‑195 suppresses cell proliferation, migration and invasion in epithelial ovarian carcinoma via inhibition of the CDC42/ccnd1 pathway.
Hao X; Jia Q; Yuan J; Shi X; Guo H; Gao J; Guo Y
Int J Mol Med; 2020 Nov; 46(5):1862-1872. PubMed ID: 32901852
[TBL] [Abstract] [Full Text] [Related]
13. ovarian mucinous tumors with mural nodules: immunohistochemical and molecular analysis of 3 cases.
Shao Y; Liu Q; Shi H; Lu B
Diagn Pathol; 2020 Apr; 15(1):35. PubMed ID: 32290854
[TBL] [Abstract] [Full Text] [Related]
14. Development of prediction models for lymph node metastasis in endometrioid endometrial carcinoma.
Berg HF; Ju Z; Myrvold M; Fasmer KE; Halle MK; Hoivik EA; Westin SN; Trovik J; Haldorsen IS; Mills GB; Krakstad C; Werner HMJ
Br J Cancer; 2020 Mar; 122(7):1014-1022. PubMed ID: 32037399
[TBL] [Abstract] [Full Text] [Related]
15. Durable response to palbociclib and letrozole in ovarian cancer with
Frisone D; Charrier M; Clement S; Christinat Y; Thouvenin L; Homicsko K; Michielin O; Bodmer A; Chappuis PO; McKee TA; Tsantoulis P
Cancer Biol Ther; 2020; 21(3):197-202. PubMed ID: 31709901
[TBL] [Abstract] [Full Text] [Related]
16. Inhibition of KIF20A by BKS0349 reduces endometriotic lesions in a xenograft mouse model.
Ferrero H; Corachán A; Quiñonero A; Bougeret C; Pouletty P; Pellicer A; Domínguez F
Mol Hum Reprod; 2019 Sep; 25(9):562-571. PubMed ID: 31365745
[TBL] [Abstract] [Full Text] [Related]
17. MicroRNA-551b-3p inhibits tumour growth of human cholangiocarcinoma by targeting Cyclin D1.
Chang W; Wang Y; Li W; Shi L; Geng Z
J Cell Mol Med; 2019 Aug; 23(8):4945-4954. PubMed ID: 31199052
[TBL] [Abstract] [Full Text] [Related]
18. Platinum-free interval affects efficacy of following treatment for platinum-refractory or -resistant ovarian cancer.
Kobayashi-Kato M; Yunokawa M; Bun S; Miyasaka N; Kato T; Tamura K
Cancer Chemother Pharmacol; 2019 Jul; 84(1):33-39. PubMed ID: 30982097
[TBL] [Abstract] [Full Text] [Related]
19. Cyclin D1 silencing impairs DNA double strand break repair, sensitizes BRCA1 wildtype ovarian cancer cells to olaparib.
Zhong Q; Hu Z; Li Q; Yi T; Li J; Yang H
Gynecol Oncol; 2019 Jan; 152(1):157-165. PubMed ID: 30414739
[TBL] [Abstract] [Full Text] [Related]
20. Overexpression of Pyruvate Kinase Type M2 (PKM2) Promotes ovarian cancer Cell Growth and Survival Via Regulation of Cell Cycle Progression Related with Upregulated ccnd1 and Downregulated CDKN1A Expression.
Zheng B; Liu F; Zeng L; Geng L; Ouyang X; Wang K; Huang Q
Med Sci Monit; 2018 May; 24():3103-3112. PubMed ID: 29752805
[TBL] [Abstract] [Full Text] [Related]
[Next]
